Dow Down0.22% Nasdaq Up0.14%

More On SHP.L

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


Shire plc (SHP.L)

-LSE
4,873.00 Down 31.00(0.63%) Aug 22, 11:38AM EDT
ProfileGet Profile for:
Shire plc
5 Riverwalk
Citywest Business Campus
Dublin, 24
Ireland - Map
Phone: 353 1 429 7700
Website: http://www.shire.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:5,338

Business Summary 

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Shire plc

Key Executives 
 PayExercised
Dr. Flemming Ornskov M.D., MBA, MPH, 56
Chief Exec. Officer, Managing Director and Director
3.40MN/A
Mr. James Bowling ,
Interim Chief Financial Officer, Sr. VP and Group Financial Controller
N/AN/A
Ms. Marianne Jackson ,
Head of Global Commercial Operations
N/AN/A
Mr. William Ciambrone ,
Head of Technical Operations
N/AN/A
Mr. Eric Rojas ,
Sr. Director of Investor Relations
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in GBp.